What Debiotech does

Debiotech SA is a privately held, ISO 13485-certified Swiss medical device development company founded in 1990 and headquartered in Lausanne, Switzerland. It conceives, designs, and develops complex hybrid medical devices spanning hardware, electronics, and software for drug delivery, dialysis, and injectable therapeutics. Its proprietary technology portfolio includes the JewelPump insulin on-body injector, DialEase peritoneal dialysis system, NextKidney portable hemodialysis system (commercialized via a 2020 joint venture), Chronoflow constant-flow bolus injector, DebioJect intradermal microneedle platform, CT-Expres IV contrast injector, DebioClip/DebioPass drug delivery devices, and large-volume wearable injectors. The portfolio is underpinned by 500+ granted national patents and 13+ registered trademarks covering device architecture, fluidic control, and delivery mechanisms.

The company operates a dual business model combining proprietary product licensing with contract development services. The licensing/royalty stream derives from over 40 license agreements covering its patented device architectures and drug delivery platforms. In 2020, Debiotech pivoted to also offer third-party medical device development services, structured around two axes: an R&D axis delivering software, mechanics, and electronics development, and a project management axis covering agile and regulatory-compliant development processes through to technical file preparation for regulatory submissions. Customers and partners include blue-chip medical device and pharmaceutical enterprises such as Pfizer, Medtronic, Baxter, Fresenius Medical Care, Bracco, Carl Zeiss Meditec, West Pharmaceutical Services, JMS, Kimal, Abbati Labs, and NASA, alongside research collaborations with entities such as the ARTORG Center at the University of Bern.

Revenue is generated through B2B direct enterprise sales with no publicly disclosed pricing; the customer base is exclusively enterprise-scale across medical devices, pharmaceuticals, medical imaging, and select adjacent verticals (aerospace). Debiotech maintains an active product roadmap including an AI-enabled mobile health application using reinforcement learning to optimize therapy delivery, signaling continued platform expansion beyond pure mechanical/fluidic devices into digital therapeutics.

Name

Debiotech

Legal name

Debiotech SA

Website

https://debiotech.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

11–50 employees

Short description

Debiotech SA is a Swiss ISO 13485-certified medical device development company that designs and licenses proprietary drug delivery, dialysis, and injection technologies while providing contract R&D services to enterprise medical device and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Medical Device Development Services

NAICS

Surgical and Medical Instrument Manufacturing (339112), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• Medical device development
• Drug delivery systems
• Dialysis systems
• Insulin delivery devices
• Microneedle technology

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Development Services: R&D services including software, mechanics and electronics development for medical devices, plus project management services for compliant medical device development processes
2. Licensing and IP Royalties: Revenue from licensing proprietary technologies and receiving royalties from developed products - the company has over 40 license agreements and 500+ granted national patents

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Debiotech is an ISO 13485-certified Swiss medical device development company that conceives, designs, and engineers innovative drug delivery, dialysis, and injection devices spanning hardware, electronics, and software. Since 2020, the company has pivoted to also provide medical device and software development services — R&D (mechanics, electronics, software) plus project management for compliant medical device development — to other companies, complemented by licensing of its proprietary technologies.

Product overview

Debiotech operates as an ISO 13485-certified medical device development company offering a portfolio of drug delivery and dialysis systems. The portfolio includes insulin delivery (JewelPump), peritoneal dialysis (DialEase), and hemodialysis (NextKidney) as core therapeutic platforms, complemented by injection systems (CT-Expres for IV, Large Volume Injectors for subcutaneous), and flow control technology (Chronoflow). The drug delivery line includes microneedle technology (Debioject) and clip-based delivery devices (DebioClip, DebioPass). An AI-enabled medical app with reinforcement learning provides smart therapy optimization capabilities. The company functions as a development services provider with proprietary systems, serving both as a product developer and a technical development partner for other medical device companies.

Differentiator

Problem solved

Functional benefit

Brands

• DialEZ: Peritoneal dialysis system
• DialEase
• JewelSet
• jewelcom
• JewelCare
• JewelCloud
• Debioject
• JewelCard
• Poseidon
• Jewelpump
• Chronoflow
• DebioClip
• DebioPass

Products and services

• JewelPump Insulin on-body injector for continuous subcutaneous insulin delivery, designed for patient convenience and compliance. Targeted at diabetes patients.
• DialEase Peritoneal dialysis system enabling patients to perform dialysis treatments at home as an alternative to hemodialysis. Targeted at kidney disease patients.
• NextKidney Hemodialysis System Portable home hemodialysis system developed jointly with Neokidney BV and commercialized through NextKidney SA, targeting end-stage renal disease patients.
• CT-Expres Intravenous injector system for contrast media delivery during CT imaging procedures. Targeted at radiology departments and medical imaging providers.
• Chronoflow Constant flow bolus injector that delivers pharmaceutical substances with a perfectly constant flow rate using a self-regulating fluidic resistance system without requiring an energy source. Flow rate ranges from 1ml/day to 100ml/h.
• DebioJect Intradermal microneedle delivery system for painless drug administration, applicable for vaccines, biologics, and cell injection.
• DebioClip and DebioPass Drug delivery devices for controlled and reliable subcutaneous drug administration, including multi-dose or sequential drug delivery applications.
• Large Volume Injectors Wearable injector platform capable of delivering large volumes (several milliliters) of viscous drugs over extended periods.
• Medical App with Reinforcement Learning Mobile health application leveraging reinforcement learning algorithms to optimize therapy delivery parameters and patient outcomes.
• Medical Device Development Services R&D and project management services supporting medical device companies from ideas and concepts through compliant design, development, and supply chain creation. Targeted at medical device manufacturers and pharmaceutical companies.

Named customers13 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• NextKidney SAcoreStrategic or Co-development Partner · 15 June 2020Debiotech SA and Neokidney BV joined forces to enable NextKidney SA to finalize the development and commercialization of the Neokidney portable home hemodialysis system. Debiotech contributed technology and expertise to create this new company entity focused on kidney disease treatment solutions.
• Vaccine Companies, Foundations and Public OrganizationscoreStrategic or Co-development Partner · 15 April 2020Collaboration with vaccine companies, foundations and public organizations using the DebioJect Microneedle technology to improve COVID-19 vaccine effectiveness and reduce required doses through microneedle vaccine delivery.
• ARTORG - University of BerncoreStrategic or Co-development Partner · 20 September 2018Successful completion of the MyTreat project in collaboration with the ARTORG Center for Biomedical Engineering Research of the University of Bern and the Division of Endocrinology, Diabetes and Clinical Nutrition. Joint research on diabetes treatment technologies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• StarFish Medical: Canadian medical device design, development, and contract manufacturing firm providing full lifecycle services from concept to commercialization, directly comparable to Debiotech's R&D and project management service axes.
• Cambridge Consultants: UK-based technology and engineering consultancy with a deep medical device development practice spanning drug delivery, diagnostics, and connected devices, comparable to Debiotech's hybrid hardware/software/electronics capabilities.
• Phillips-Medisize: Global medical device CDMO offering design, development, and manufacturing services for drug delivery and combination products, directly overlapping with Debiotech's insulin pump, injector, and connected device offerings.
• Velentium: US-based medical device engineering services firm specializing in connected, secure, and software-intensive medical devices, highly comparable to Debiotech's expertise in hybrid hardware-electronics-software development.
• Donatelle: US medical device contract developer and manufacturer focused on complex Class II/III devices including drug delivery and diagnostics, comparable to Debiotech's regulated device development capabilities.

Broad incumbents

• Flex: Large global contract manufacturer with a substantial healthcare and medical device division offering design, engineering, and manufacturing at a scale that dwarfs Debiotech, competing for outsourced medical device programs.
• Jabil Healthcare: Global manufacturing services provider with a dedicated healthcare division spanning medical device design, manufacturing, and supply chain, a broader incumbent competing for the same outsourced development work as Debiotech.
• Gerresheimer: European-headquartered specialty manufacturer of pharmaceutical and medical devices including injectors and drug delivery systems, comparable as a broader incumbent with overlapping drug delivery and device capabilities.
• Becton Dickinson: Major global medical technology company with significant drug delivery, injection, and diagnostics franchises; not a direct service competitor but a broad incumbent in the device categories Debiotech develops for.
• Medtronic: Largest pure-play medical device company globally with extensive diabetes, dialysis, and drug delivery franchises; a current Debiotech customer but also a broad incumbent whose vertical integration could displace outsourced development demand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/debiotech-sa

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Debiotech